The advent of tumor immunotherapy heralds a significant leap towards addressing malignant afflictions including gastric, colorectal, and lung cancers, showcasing substantial therapeutic advancements. However, the universal applicability of immunotherapy remains elusive, with certain patient groups and specific tumor types showcasing resistance or non-responsiveness to such treatments. Intratumor heterogeneity, emanating from diverse genetic, cellular, and tissue landscapes, is postulated to be a critical underpinning of this disparate therapeutic responsiveness. The convoluted nature of cancer, underscored by its broad genetic and phenotypic spectrum, further compounds the challenge in harnessing immunotherapy's full potential.
The primary objective of this Research Topic is to provide a dedicated platform for the dissemination of pioneering research, novel insights, and methodological advancements aimed at demystifying the enigma of intratumor heterogeneity and its impact on immunotherapeutic efficacy. By fostering a rigorous academic discourse around this pivotal issue, we aspire to propel forward the understanding of the underlying mechanisms mediating intratumor heterogeneity and immunotherapy resistance. Through this scholarly endeavor, we envision bridging theoretical knowledge with practical applications in cancer medicine, thereby contributing to more personalized and effective immunotherapeutic strategies.
We invite submissions of Original Research articles, Comprehensive Reviews, and Insightful Commentaries that delve into the molecular, cellular, and systemic aspects of intratumor heterogeneity and its interplay with immunotherapeutic approaches. Through a rigorous peer-review process, we aim to ensure the highest level of scholarly integrity, while promoting a vibrant academic dialogue to foster breakthroughs in the field of cancer immunotherapy.
Topics of interest include:
(1) Role of non-mutational epigenetic reprogramming, polymorphic microbiomes, senescent cells, and phenotypic plasticity in mediating immunotherapeutic responsiveness.
(2) Exploring novel computational and experimental tools aimed at elucidating the multifaceted nature of intratumor heterogeneity.
(3) Leveraging the “big data” paradigm to advance the understanding and overcoming of the hurdles posed by intratumor heterogeneity in the realm of immunotherapy, from a multidisciplinary perspective.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Keywords:
Intratumor Heterogeneity
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The advent of tumor immunotherapy heralds a significant leap towards addressing malignant afflictions including gastric, colorectal, and lung cancers, showcasing substantial therapeutic advancements. However, the universal applicability of immunotherapy remains elusive, with certain patient groups and specific tumor types showcasing resistance or non-responsiveness to such treatments. Intratumor heterogeneity, emanating from diverse genetic, cellular, and tissue landscapes, is postulated to be a critical underpinning of this disparate therapeutic responsiveness. The convoluted nature of cancer, underscored by its broad genetic and phenotypic spectrum, further compounds the challenge in harnessing immunotherapy's full potential.
The primary objective of this Research Topic is to provide a dedicated platform for the dissemination of pioneering research, novel insights, and methodological advancements aimed at demystifying the enigma of intratumor heterogeneity and its impact on immunotherapeutic efficacy. By fostering a rigorous academic discourse around this pivotal issue, we aspire to propel forward the understanding of the underlying mechanisms mediating intratumor heterogeneity and immunotherapy resistance. Through this scholarly endeavor, we envision bridging theoretical knowledge with practical applications in cancer medicine, thereby contributing to more personalized and effective immunotherapeutic strategies.
We invite submissions of Original Research articles, Comprehensive Reviews, and Insightful Commentaries that delve into the molecular, cellular, and systemic aspects of intratumor heterogeneity and its interplay with immunotherapeutic approaches. Through a rigorous peer-review process, we aim to ensure the highest level of scholarly integrity, while promoting a vibrant academic dialogue to foster breakthroughs in the field of cancer immunotherapy.
Topics of interest include:
(1) Role of non-mutational epigenetic reprogramming, polymorphic microbiomes, senescent cells, and phenotypic plasticity in mediating immunotherapeutic responsiveness.
(2) Exploring novel computational and experimental tools aimed at elucidating the multifaceted nature of intratumor heterogeneity.
(3) Leveraging the “big data” paradigm to advance the understanding and overcoming of the hurdles posed by intratumor heterogeneity in the realm of immunotherapy, from a multidisciplinary perspective.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Keywords:
Intratumor Heterogeneity
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.